To examine changes in, and relationships between, sleep quality and quantity, salivary testosterone, salivary cortisol, testosterone-to-cortisol ratio (T:C), and self-reported muscle soreness during a residential-based training camp in elite rugby players. Nineteen male rugby players age 26.4 (3.9) years, height 186.0 (9.4) cm, and weight 104.1 (13.4) kg (mean [SD]) participated in this study. Wrist actigraphy devices were worn for 8 nights around a 4-d training camp (2 nights prior, during, and 2 nights after). Sleep-onset latency, sleep duration, sleep efficiency, and waking time were measured. Participants provided saliva samples during camp on waking and again 45 min later, which were then assayed for testosterone and cortisol levels. They also rated their general muscle soreness daily. Little variation was observed for sleep quality and quantity or testosterone. However, significant differences were observed between and within days for cortisol, T:C, and muscle soreness ( < .001). Few relationships were observed for sleep and hormones; the strongest, an inverse relationship for sleep efficiency and T:C ( = -.372,  < .01). There may be no clear and useful relationship between sleep and hormone concentration in a short-term training camp context, and measures of sleep and testosterone and cortisol should be interpreted with caution because of individual variation. Alterations in hormone concentration, particularly cortisol, may be affected by other factors including anticipation of the day ahead. This study adds to our knowledge that changes in hormone concentration are individual and context specific.

Download full-text PDF

Source
http://dx.doi.org/10.1123/ijspp.2018-0600DOI Listing

Publication Analysis

Top Keywords

muscle soreness
12
salivary testosterone
8
testosterone cortisol
8
sleep quality
8
quality quantity
8
training camp
8
rugby players
8
sleep
5
sleep salivary
4
testosterone
4

Similar Publications

Impact of fluconazole on outcomes of patients with primary pulmonary coccidioidomycosis: a commercial health insurance claims-based, propensity score matched analysis.

Clin Infect Dis

January 2025

Department of Medicine, Division of Infectious Diseases, and the Department of Medical Microbiology and Immunology, University of California, Davis, Sacramento, California, USA.

Background: Patients with pulmonary coccidioidomycosis often experience prolonged symptoms lasting weeks to months. Limited data exist regarding whether fluconazole prevents development of disseminated disease or shortens symptom duration. We describe factors associated with fluconazole receipt and assess its effect on outcomes among patients with pulmonary coccidioidomycosis.

View Article and Find Full Text PDF

Neurochemical mechanism of muscular pain: Insight from the study on delayed onset muscle soreness.

J Physiol Sci

January 2025

Department of Physical Therapy, Faculty of Rehabilitation, Niigata University of Health and Welfare, 950-3198, Niigata, Japan; Institute for Human Movement and Medical Sciences (IHMMS), Niigata University of Health and Welfare, 950-3198, Niigata, Japan.

We reviewed fundamental studies on muscular pain, encompassing the characteristics of primary afferent fibers and neurons, spinal and thalamic projections, several muscular pain models, and possible neurochemical mechanisms of muscle pain. Most parts of this review were based on data obtained from animal experiments, and some researches on humans were also introduced. We focused on delayed-onset muscle soreness (DOMS) induced by lengthening contractions (LC), suitable for studying myofascial pain syndromes.

View Article and Find Full Text PDF

Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.

Rev Inst Med Trop Sao Paulo

January 2025

Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, Laboratório de Investigação Médica em Imunologia (LIM-48), SSão Paulo, São Paulo, Brazil.

Immunocompromised individuals were considered high-risk for severe disease due to SARS COV-2 infection. This study aimed to describe the safety of two doses of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan), followed by additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised (IC) adults, compared to immunocompetent/healthy (H) individuals. This phase 4, multicenter, open label study included solid organ transplant and hematopoietic stem cell transplant recipients, cancer patients and people with inborn errors of immunity with defects in antibody production, rheumatic, end-stage chronic kidney or liver disease, who were enrolled in the IC group.

View Article and Find Full Text PDF

Background: Cardiovascular, respiratory, and musculoskeletal disease are among the leading causes of disability in middle-aged and older people. Health and lifestyle factors in youth have known associations with cardiovascular or respiratory disease in adulthood, but largely unknown associations with musculoskeletal disease.

Methods And Findings: We included approximately 40,000 18-year-old Swedish males, who completed their conscription examination in 1969 to 1970, followed up until age of 60 years.

View Article and Find Full Text PDF

Pain may be an early symptom of COVID-19 infection, most commonly seen as myalgia and headache. However, atypical presentations such as abdominal pain and leg pain can also be observed. We present seven cases of COVID-19 treated for pain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!